Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.85)
# 1,735
Out of 5,172 analysts
90
Total ratings
34.52%
Success rate
10.73%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INMB INmune Bio | Upgrades: Buy | $2 → $9 | $1.17 | +669.23% | 1 | Mar 11, 2026 | |
| XOMA XOMA Royalty | Initiates: Buy | $76 | $28.71 | +164.72% | 1 | Dec 9, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.51 | +4,270.86% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.25 | +4,624.41% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $0.08 | +13,650.00% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $55.21 | -9.44% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $0.92 | +1,747.83% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.07 | +1,208.41% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.60 | +2,476.92% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $21.47 | +100.28% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.21 | +327.55% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.91 | +720.03% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.49 | +329.80% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $5.41 | +602.40% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.80 | +4,918.82% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.73 | +642.94% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.33 | +3,655.87% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $13.97 | +136.22% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $17.21 | +132.42% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.28 | +13,119.01% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.76 | +373.37% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $6.63 | +1,061.39% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.60 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $56.33 | -11.24% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $1.81 | +1,723.20% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.00 | +136.36% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $251.68 | -88.87% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.45 | +19,001.12% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $8.18 | +156.72% | 2 | Jul 12, 2017 |
INmune Bio
Mar 11, 2026
Upgrades: Buy
Price Target: $2 → $9
Current: $1.17
Upside: +669.23%
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $28.71
Upside: +164.72%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.51
Upside: +4,270.86%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.25
Upside: +4,624.41%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $0.08
Upside: +13,650.00%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $55.21
Upside: -9.44%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $0.92
Upside: +1,747.83%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.07
Upside: +1,208.41%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.60
Upside: +2,476.92%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $21.47
Upside: +100.28%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.21
Upside: +327.55%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.91
Upside: +720.03%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.49
Upside: +329.80%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.41
Upside: +602.40%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.80
Upside: +4,918.82%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.73
Upside: +642.94%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.33
Upside: +3,655.87%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $13.97
Upside: +136.22%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $17.21
Upside: +132.42%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.28
Upside: +13,119.01%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.76
Upside: +373.37%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $6.63
Upside: +1,061.39%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.60
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $56.33
Upside: -11.24%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $1.81
Upside: +1,723.20%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.00
Upside: +136.36%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $251.68
Upside: -88.87%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.45
Upside: +19,001.12%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $8.18
Upside: +156.72%